ACTR-38. A PHASE I TRIAL OF AFATINIB AND RADIOTHERAPY (RT) WITH OR WITHOUT TEMOZOLOMIDE (TMZ) IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM)

GBM is the most frequent primary CNS tumor. RT + TMZ represents first-line therapy. ErbB pathway dysregulation contributes to GBM pathogenesis; EGFR activation is associated with RT resistance. This 3 + 3 dose-escalation study assessed afatinib, an irreversible ErbB family blocker, with RT ± TMZ in...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Neuro Oncol
Auteurs principaux: Saran, Frank, James, Allan, McBain, Catherine, Jefferies, Sarah, Harris, Fiona, Cseh, Agnieszka, Pemberton, Karine, Schaible, Jennifer, Bender, Shaun, Brada, Michael
Format: Artigo
Langue:Inglês
Publié: Oxford University Press 2018
Sujets:
Abstracts
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6216362/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy148.071
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires